Search

Objective Doxorubicin (DOX), an anthracycline antibiotic, is a drug used in the treatment of various types of cancer. It causes damage to organs such as lung, kidney, heart, liver, brain and ovary as a result of apoptosis, inflammation, free radical formation, mitochondrial DNA damage. Agomelatine (AGO) is an agonist of the powerful antioxidant melatonin. Anti-inflammatory and antioxidant activity of AGO in heart, brain, kidney, liver and ovary tissues has been demonstrated by various studies. In this study, we aimed to determine the protective effect of AGO on the toxicity of doxorubicin in the uterine tissue. Material and Method This study was carried out on 32 rats, 8 female rats in each group. Experimental groups: Control was formed from 4 groups as DOX, DOX+AGO20 and DOX+AGO40. The rats in the control group were given 1 ml of saline (SF) once a day by oral gavage for 12 days and intraperitoneally only on the 12th day. The animals in the DOX group were given 1 ml of saline by oral gavage every day for 12 days and a single dose of 40 mg/kg DOX intraperitoneally (i.p.) on the 12th day. Animals in the DOX+AGO20 group were given 20 mg/kg AGO by oral gavage method every day for 12 days. On the 12th day, i.p. 40 mg/kg DOX was given. Animals in the DOX+AGO40 group were given 40 mg/kg AGO by oral gavage method every day for 12 days. On the 12th day, i.p. 40 mg/kg DOX was given. Results As a result of the histopathological procedures and examinations, it was observed that the damage to the uterine tissues of the DOX group was reduced in the groups that were administered DOX+ AGO20 and DOX+AGO40 combined. As a result of immunostaining (E-cadherin and eNOS), it was determined that the staining intensity was higher in the DOX group and less in the DOX+ AGO20 and DOX+AGO40 combined groups. Conslusion As a result, we think that AGO has a protective effect against the damage caused by DOX in the uterine tissue. [ABSTRACT FROM AUTHOR]

Abstract Background Although various pharmacological and nonpharmacological treatments are available for the chronic low back pain (CLBP), there is no consensus on the best optimal treatment for this condition. This study aimed to investigate the efficacy of co-administration of pregabalin and agomelatine versus pregabalin with placebo to treat CLBP. Methods Forty-six CLBP patients without the surgical indication referred to the outpatient orthopedic clinic of Rasoul-e-Akram Hospital, Tehran, Iran, were randomly divided into two study groups: Group A [pregabalin (75 mg twice per day) + placebo] and Group B [pregabalin (75 mg twice per day) + agomelatine (25 mg per night)]. Patients were evaluated at weeks 0, 4, and 8. Outcome measures were the Persian versions of the Brief Pain Inventory (BPI) interference scale, Roland-Morris Disability Questionnaire (RMDQ), The Hospital Anxiety and Depression Scale (HADS), 36-Item Short Form Survey (SF-36), and General Health Questionnaire-28 (GHQ-28) were used. Results At weeks 4 and 8 after the intervention, all evaluated measures showed significant improvement in both study groups (P

ObjectiveTo evaluate the efficacy and safety of agomelatin and selective serotonin reuptake inhibitors （SSRIs） in the treatment of depressive disorder via network Meta-analysis.MethodsThe literature databases such as China National Knowledge Network （CNKI）， Wanfang Data Knowledge Service Platform， VIP Database for Chinese Technical Periodical （VIP）， Chinese Biomedical Literature Database （CBM）， PubMed， Embase and Cochrane Library were searched from the inception to November 2021. Based on the preset inclusion and exclusion criteria， literature screening， quality assessment of methodology and data extraction were conducted by two researchers separately， then statistical analysis was carried out using ADDIS software.ResultsA total of 7 256 patients with depressive disorder in 22 randomized controlled trials were included. According to the consistency assessed in Bayesian network Meta-analysis and the estimation of the probability of being the best treatment， escitalopram （P=0.63） ranked first for response rate and paroxetine （P=0.31） was associated with the best ranking for cure rate in terms of the effectiveness， meantime， paroxetine （P=0.44） had the highest adverse events risk and sertraline （P=0.74） had the highest study drop-outs proportion in terms of safety.ConclusionEscitalopram and paroxetine may be superior to sertraline， agomelatine， citalopram and fluoxetine in the treatment of depressive disorder， furthermore， paroxetine and sertraline demonstrate poor safety profiles.

Background: Although various pharmacological and nonpharmacological treatments are available for the chronic low back pain (CLBP), there is no consensus on the best optimal treatment for this condition. This study aimed to investigate the efficacy of co-administration of pregabalin and agomelatine versus pregabalin with placebo to treat CLBP. Methods: Forty-six CLBP patients without the surgical indication referred to the outpatient orthopedic clinic of Rasoul-e-Akram Hospital, Tehran, Iran, were randomly divided into two study groups: Group A [pregabalin (75 mg twice per day) + placebo] and Group B [pregabalin (75 mg twice per day) + agomelatine (25 mg per night)]. Patients were evaluated at weeks 0, 4, and 8. Outcome measures were the Persian versions of the Brief Pain Inventory (BPI) interference scale, Roland-Morris Disability Questionnaire (RMDQ), The Hospital Anxiety and Depression Scale (HADS), 36-Item Short Form Survey (SF-36), and General Health Questionnaire-28 (GHQ-28) were used. Results: At weeks 4 and 8 after the intervention, all evaluated measures showed significant improvement in both study groups (P < 0.01). The mean improvement of GHQ-28 was 3.7 ± 1.22 in group A and 13.1 ± 4.71 in group B. This difference was statistically significant (P = 0.003). Other outcomes did not vary substantially between the two research groups. Agomelatine treatment was well tolerated, with no significant adverse effects seen in patients. Liver tests of all patients were routine during the study period. Major adverse effect was not seen in any patient. The prevalence of Minor side effects was not significantly different between two study groups. Conclusion: Compared with the pregabalin and placebo, co-administration of pregabalin and agomelatine had no added effect on improving pain scores in CLBP patients. However, the patients' general health was significantly improved after the combined administration of pregabalin and agomelatine. Trial registration: The study protocol was registered in the Iranian Registry of Clinical Trials before starting the study (NO.IRCT20200620047852N1, Registration date: 23/06/2020). [ABSTRACT FROM AUTHOR]

A simple and precise reversed-phase high-performance liquid chromatographic (HPLC) method was developed for the separation of Agomelatine and its impurities in the tablet dosage form. The method was developed by utilizing the quality by design (QbD) statistical approach. The method optimized as pH 2.6 buffer containing potassium dihydrogen orthophosphate (KH2PO4) and 1-octane sulphonic acid sodium salt anhydrous and Acetonitrile in the ratio of 80:20 (v/v) as mobile phase A and Milli-Q water and acetonitrile in the ratio of 20:80 (v/v) as mobile phase B in gradient elution and separation was achieved on Symmetry Shield RP-18, 150 X 4.6 mm, 3.5 µm column as stationary phase and UV detection at 230nm. The quantitation limits of Agomelatine AGL-5D impurity, Desmethyl impurity, 5th Isomer impurity, AGL-4D impurity, and hydroxy impurities are found to be 0.05, 0.04, 0.06, 0.05, and 0.04 respectively. Recovery studies from (limit of quantification level to 150% level) 0.05 µg/mL to 150 µg/mL are performed for all impurities and results are in the range of 97.5-101.2%. The method can separate impurities studied and the forced degradation compounds formed and hence the method can effectively use for the analysis of impurities of Agomelatine and stress degradation compounds. [ABSTRACT FROM AUTHOR]

Copyright of Online Turkish Journal of Health Sciences (OTJHS) / Online Türk Sağlık Bilimleri Dergisi is the property of Oguz KARABAY and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

INTRODUCTION: Parkinson disease is one of the most common neurodegenerative disorders. This disease still have no exact cure. Agomelatin is the synthetic analog of melatonin hormone that is synthesized in pineal gland and then released from there. Agomelatin shows its antidepressant effects on central nervous system (CNS) by activating MT1 and MT2 receptors caused by melatonin and by antagonizing serotonin 5-HT2C receptors caused by monoamine. In this study, we examined the effects of oral Agomelatin administration on rats, which had experimental Parkinson disease formed by utilizing 6-OHDA. METHODS: We administered unilateral intrastriatal 6-OHDA on 45 rats weighing 270-330 gr, in three different groups. We applied dissolver on control group; in other two groups we administered 5 mg/kg/day and 20 mg/kg/day Agomelatin respectively, for 15 days. At the end of this treatment process, motor coordination and skills were tested with sticky band test, open-field test and cylinder test, whereas, dopaminergic damage degree was tested with apomorphine induced rotation test. RESULTS: In our study, we found out that in both groups in which Agomelatin was administered (5 mg/kg/day and 20 mg/kg/day respectively), Agomelatin prevented progression of experimental Parkinson disease formed with 6-OHDA in rats. DISCUSSION AND CONCLUSION: Agomelatin showed a protective effect on striatal neurons damage in experimental Parkinson's Disease model.

There are described practical aspects of antidepressant treatment and switch of antidepressant medication in this article. We introduce several types (strategies) of antidepressant switch. We recomend the initiation of agomelatine treatment with long-tapering of the previous medication to decrease the risk of withdrawal syndrome onset. The agomelatine treatment and combination with other antidepressants is effective and well tolerated. The dose increase of agomelatine from 25 mg to 50 mg is recomended in patients who do not respond. This article contains several case-reports. [ABSTRACT FROM AUTHOR]

Agomelatine, a MT1 (Melatonin) and MT2 receptor agonist and 5-HT2C (5-Hidroksitriptamin) antagonist, is an antidepressant agent used in the treatment of major depressive disorders. Intraocular pressure lowering effect of melatonin and its analogues have been demonstrated in a few experimental studies. In the present case report, we have documented the reversal of angle closure glaucoma by oral agomelatine in a patient with major depressive disorder under selective serotonine reuptake inhibitor treatment. The patient, who had previously been diagnosed with glaucoma, was also receiving antiglaucomatous treatment. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Dr. Behcet Uz Children's Hospital is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Diabetes is a multisystem disorder and its effects are observed on the reproductive system. One of the main causes of testicular tissue damage is diabetes-induced overproduction of reactive oxygen species and glycated end products. The main objectives of this study were to investigate the possible effects of agomelatine (AG) and gallic acid (GA) in suppressing oxidative stress in Type I diabetes induced testicular damage. A total of 28 adult male rats were included in the study. Diabetes was induced by intraperitoneal injection of streptozocin (STZ, 55 mg/kg) to 21 rats, which were then randomly assigned to 3 groups; 1 mL saline solution was given to the diabetes + saline group by oral gavage, 20 mg/kg/day oral AG was given to the diabetes + AG group , and 20 mg/kg/day oral GA was given to the diabetes + GA group for 4 weeks. Tumor necrosis factor α (TNFα), nitric oxide synthase 2 (NOS2), fibronectin and vascular endothelial growth factor (VEGF) were used for the investigation of inflammation, fibrosis and vascular structures. The terminal-deoxynucleoitidyl-transferase mediated nick end-labeling assay (TUNEL) was used to detect apoptosis. Testicular tissue total antioxidant capacity values were tested by biochemical analysis. AG treatment showed an improvement on biochemical parameters and histopathological appearance on the rat testes. GA showed dose-related regenerative effects on biochemical parameters. Histologically, a minimal healing effect was determined on the testes damage. In conclusion, it was observed that AG is a potentially beneficial agent for reducing testicular damage by decreasing oxidative stress level. However, GA was seen to have a poor therapeutic effect. [ABSTRACT FROM AUTHOR]

Copyright of Turkish Journal of Trauma & Emergency Surgery / Ulusal Travma ve Acil Cerrahi Dergisi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Wiener Klinische Wochenschrift is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: Agomelatine is a naphthalene bioisostere of melatonin. Melatonin is involved in several neurophysiological systems; nevertheless, data about the relationship between melatonin and psychosis such as schizophrenia are limited and contradictory. In this study, we examined the antipsychotic-like effects of agomelatine in a rodent model. Method: In this study, we evaluated the effect of agomelatine on novelty-induced rearing behavior and apomorphine-induced stereotypical behavior in male rats. Agomelatine (20 and 40mg/kg, i.p.), chlorpromazine (1mg/kg, i.p.), or isotonic NaCl (1mL/kg, i.p.) were administered to four groups of rats (n=6), respectively. An hour later, apomorphine (2mg/kg, s.c.) was administered to each rat. Results: Our results showed that either dose of agomelatine decreased rearing behavior in rats significantly, in a dose dependent manner. Agomelatine also decreased the stereotypical behaviour scores like chlorpromazine did. Conclusion: We conclude that agomelatine has beneficial effects on rearing and stereotypical behaviour, which were accepted to be indicators of antipsychotic effect. [ABSTRACT FROM AUTHOR]

Objective: The aim of the study was to study the effects of agomelatine, an antidepressant, on the nociceptive system. Methods: Twenty four male Swiss albino mice (four months old and 28.8±1.18 g average weight) were randomly divided into three groups, which were equal in numbers; Group A and B were the experimental groups and group C was the control group. Group A was given 12.5 mg/kg of agomelatine, Group B was given 25 mg/kg agomelatine and Group C was given physiological saline via intraperitoneal injection. To evaluate the nociceptive effects, by using the hot plate method (50°C), pain threshold values of the control and agomelatine groups were recorded as the 30th and 60th minute findings. Results: According to the pain threshold results, the datafor the two agomelatine groups were found to be higher than control group at both time points. In 30th minute measurements, between Group B and the other groups, significant differences were observed (p=0.007). In addition, significance in the interaction between time and group was observed (p=0.036). Conclusions: The results of the study suggest that agomelatine might have analgesic efficacy on the nociceptive system in mice. [ABSTRACT FROM AUTHOR]

In this article literature related to the promises of agomelatine, an antidepressant with melatonergic MT-1 and MT- 2 receptor agonism and seratoninergic 5-HT2c receptor antagonism in the context of depression treatment is reviewed. Although the results of studies on the efficacy of agomelatine are contrary, it can be stressed that the efficacy of agomelatine should be at least similar to widely used antidepressants. Furthermore the favorable effect of agomelatine on sleep and the early onset of efficacy should contribute to the outcome of therapy. The favorable effect of agomelatine on the circadian rhythm which has influence on substantial biological systems like sleepwake cycle, endocrine hormone secretion and body temperature appears to be interesting. Somnolence should be noted as a more frequent adverse event of agomelatine than other antidepressants. Furthermore the absence of weight gain and sexual adverse events should influence the adherence to therapy. Liver enzyme elevations can emerge during agomelatine therapy. Abrupt discontinuation of agomelatine does not appear to bring about evident discontinuation symptoms. [ABSTRACT FROM AUTHOR]

Adaptation is a continuous process between the genes of a particular species and its environment. Although a couple of weeks are long enough to adapt to some environmental changes. sometimes several generations are needed to adapt. Rapid and sustained environmental changes, however, exceed the adaptation capacity of species and cause gene-environment discordance. Genomes of individuals, who live at the beginning of such discordance, are adapted to the previous environment and therefore physiological mechanisms of the organism are influenced by this novel circumstance. The disrupted interaction between individual and environment appears as diseases, increased morbidity, and mortality in the phenotype. Diseases of civilizations which are the reflections of gene-environment discordance tend to accumulate into several main groups such as metabolic (e.g., cardiovascular, diabetes, hypertension, obesity and metabolic syndrome), reproductive (male and female infertility), neurodegenerative (e.g., Alzheimer, dementia) and some psychiatric disorders (e.g., major depression, bipolar disorders). In spite of the fact that the pathophysiology of many neuropsychiatric disorders are not well known, since symptoms including sleep and appetite problems, fatigue, loss of libido and concentration as well as metabolic disorders may coexist, it is considered that neuropsychiatric disorders may have a complex neurobiological basis. Some scientists have referred to this situation as a "neuropsychiatric syndrome" or "type II metabolic syndrome". Data obtained from metabolic syndrome studies may be adapted to type II metabolic syndrome to clarify the biological basis of the disease. As seen in metabolic syndrome, the neuropsychiatric syndrome may also develop in a broken physiological infrastructure. Some of the disrupted physiological mechanisms shown in metabolic syndrome may be summarized as the mismanaged autonomic nervous system (ANS), reduced central and peripheral GABA production, and epigenetic perturbations which have recently become very popular. ANS dysregulation is closely related to recent treatment modalities such as vagal nerve stimulation (VNS) and light therapy (LT). Both modalities are based on the re-regulation of an already dysregulated autonomic rhythm. Secretion of melatonin from the pineal gland is one of the effective mechanisms in the regulation of ANS. Since melatonin is only used for the treatment of jet-lag and sleep problems, the range of treatment indications with melatonin has remained limited for years. Nevertheless, central effects of melatonin play an important role in the treatment of depression and similar disorders. Therefore, melatonin has been recently used to treat neuropsychiatric syndrome. Moreover, a severe familial tendency in neuropsychiatric disorders has long been recognised. Even so, no genetic defects (e.g., mutation, deletion and insertion) have been found to explain the familial tendency. Therefore, it was hypothesized that epigenetic inheritance rather than genetic mechanisms may have a role in the pathogenesis of disease and it was proved that epigenetic disruptions play crucial roles in the pathogenesis of neuropsychiatric syndrome. Melatonin, as an impressive epigenetic regulator may have potential in the treatment of some neuropsychiatric disorders. Articles used for current review were published between 1977 and 2008 and obtained from Pubmed database by using keywords including melatonin, agomelatine, autonomic nervous system, and depression. The purpose of this paper is to find out whether there it a gene-environment discordance in the pathogenesis of neuropsychiatric disorders and to discuss the role of ANS and melatonin in these circumstances. [ABSTRACT FROM AUTHOR]

Objective: It is known that depression reduces the pain threshold and neurogenesis. New drugs for the treatment of depression and secondary effects of depression continue to be produced. Despite these drugs, depression is still an important health problem. The aim of this study was to show the effect of agomelatine on neurogenesis and pain threshold in depressive rats. Methods: 40 male Wistar albino rats (10-12 weeks old) were used in the study. Rats were divided into four groups as control (CONT), control-agomelatine (KONT-AGO), depression (DEP), depression-agomeletin (DEP-AGO) groups. Depression model was developed based on the method developed by Porsolt and saline applied to this group for 15 days. DEP-AGO group was administered agomelatin (1 mg/kg) with gavage for 15 days after the depression model was developed. CONT-AGO was applied agomelatin (1 mg/kg) for 15 days without ZST. Sucrose preference test was applied to all groups. The pain thresholds were measured with hot plate and tail flick methods of all groups. Sections from the hippocampus region of the brain were taken and neurogenesis was demonstrated by evaluating doublecortin (DCX) immunoreactivity intensity. Statistical comparisons between groups were evaluated by one-way ANOVA followed post-hoc LSD test. Results: When the sucrose preference, pain threshold (avoidance times) and DCX immunoreactivity were evaluated, it was found that DEP group rats decreased significantly compared that in CONT and CONT-AGO group (p<0.05). In addition, when the same parameters were evaluated, it was found that DEP-AGO group rats increased significantly compared to DEP group (p<0.05). No significant difference was found between the CONT, CONT-AGO and DEP-AGO groups (p>0.05). Conclusion: Study findings support that depression decreases pain threshold and neurogenesis and that melatonin analog agomelatine, which is used as antidepressant, normalizes these effects of depression. [ABSTRACT FROM AUTHOR]

Major depression is one of the most frequently seen psychiatric disorders. Classical antidepressant treatments might be insufficient in treating all symptoms of of depression. Therefore, antidepressant treatments which work through different mechanisms have been developed. One of these therapies is agomelatine. Agomelatine is a drug which is a synthetic analogue of melatonin hormone. Melatonin works by stimulating the activities of MT1 and MT2 receptors and inhibiting the activity of serotonin 5HT2C receptor. It is recommended to be cautious in patients taking agomelatine in terms of liver enzyme elevation. In this case report, agomelatine-induced elevation of liver enzymes and the treatment process will be presented. [ABSTRACT FROM AUTHOR]

The article presents the literature data that determine the place of antidepressants in the relief and maintenance therapy for recurrent depression (RD) and depression in the framework of bipolar affective disorder (BPAD) and provides a justification for their use in the presence of residual depressive symptoms during remission. There are several ways to achieve complete remission: determination of the nature of residual symptoms; identification of adverse side-effects that have occurred as a result of the therapy; the establishment of those symptoms that are subjectively perceived by the patient as interfering with his/her full life. The data on the effective use of agomelatin for maintenance therapy, both as monotherapy and in combination with other antidepressants, anticonvulsants and neuroleptics, in RD and BPAD are presented. The authors have analyzed the case histories of 29 outpatients with depressions of various origins (RDD, BPAD, prolonged psychogenic depression, organic affective disorder), who received agomelatin as part of complex and monotherapy for a long time (1 to 13 years), and justified the predictors of its efficacy.

Amaç: Doksorubisin, kemoterapide geniş kullanımı alanı olan antrasiklin grubu antineoplastik bir ilaçtır. Doksorubisinin kullanımını kısıtlayan en önemli yan etki doza bağımlı olarak ortaya çıkan kardiyomiyopatidir. Melatonin güçlü bir antioksidan ajan olarak birçok hastalığın patofizyolojik sürecinde olumlu etki gösterdiği bulunmuştur. Çalışmamızda doksorubisine bağlı kardiyotoksisitesinin önlenmesinde; kardiyoprotektif etkisi bilinen melatonin ile karşılaştırmalı olarak agomelatinin etkisinin Tc-99m pyrophosphate sintigrafisi ile gösterilmesi amaçlanmıştır. Yöntem: Çalışmada 2-3 aylık Wistar-Albino cinsi 49 adet rat aşağıda belirtildiği gibi yedi gruba ayrıldı: Kontrol grubu (herhangi bir işlem yapılmadı, n=7), doksorubisin grubu (deneyin 5.-7. günlerinde doksorubisin kümülatif doz 18 mg/kg, i.p. uygulandı, n=7), melatonin grubu (7 gün boyunca melatonin 40 mg/kg i.p. uygulandı, n=7), agomelatin grubu (7 gün boyunca agomelatin 40 mg/kg i.p. uygulandı, n=7), melatonin + doksorubisin grubu (7 gün boyunca melatonin 40 mg/kg i.p. ve 5.-7. günlerde doksorubisin kümülatif doz 18 mg/kg, i.p. uygulandı, n=7), agomelatin + doksorubisin grubu (7 gün boyunca agomelatin 40 mg/kg ve 5.-7. günlerde doksorubisin kümülatif doz 18 mg/kg, i.p. uygulandı, n=7) ve melatonin + agomelatin + doksorubisin grubu (7 gün boyunca melatonin 40 mg/kg, agomelatin 40 mg/kg ve ayrıca 5.-7. günlerde doksorubisin kümülatif doz 18 mg/kg, i.p. uygulandı, n=7). Çalışma bitiminde tüm gruplara 1 mCi Tc-99m pyrophosphate radyonüklidi intraperitoneal yolla enjekte edildi. Gama kamerada 1 saat sonra 10 dakikalık statik görüntüleme yapıldı ve etkilenen kalp kası bölgesinden ve vücut geri plan regions of interest (ROI) değerleri ölçülüp ortalaması alındı (Resim 1). Bulgular: Tc-99m pyrophosphate görüntülemesi sonrası doksorubisin grubunda kontrol grubuna göre yüksek oranda radyonüklid tutulumu görüldü (p<0,001). Melatonin + doksorubisin ve agomelatin + doksorubisin grubunda; doksorubisin grubuna göre düşük düzeyde radyonüklid tutulumu izlendi (p<0,01). Melatonin ve agomelatin birlikteliği ise daha fazla kardiyoprotektif etki oluşturmadı (Grafik 1). Melatonin deneysel hayvan modellerinde apoptozisi önleyen antioksidan bir ajandır. Sonuç: Çalışma sonucunda doksorubisin kullanımına bağlı oluşan kardiyotoksisitenin önlenmesinde melatonin ve agomelatin uygulamasının etkili olabileceği ve Tc-99m pyrophosphate sintigrafisinin doksorubisin kullanan kemoterapi hastaların takibinde kullanılabileceği düşünüldü. [ABSTRACT FROM AUTHOR]

Anhedonia is one of the core features of depression. The article considers the place of anhedonia in the structure of affective disorders, its influence on the prognosis and effectiveness of therapy. The authors stress that various manifestations of anhedonia must be considered in correlation with the basic ability to feel pleasure. Therapy of anhedonia is not always effective. According to literature, agomelatin occupies a leading position among the drugs that reduce anhedonia.

The objective of this review is to compare results of network metaanalyses of the efficacy and tolerability of different antidepressants for treatment of unipolar depression in adults. An analysis of different criteria of antidepressant efficacy and tolerability showed the benefits of agomelatine. Results of using this drug in national clinical practice and multicenter studies of depression of different nosology with heterogeneous psychopathological symptoms support this notion.